Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amylin, Lilly End Exenatide Tie-Up, Marking End To Litigation

08 Nov 2011

• By Paul Bonanos

Related Content

Caught Between Two Partners: Amylin Seeks To Block Lilly's Byetta Sales Force From Marketing Tradjenta

16 May 2011

Lilly Sales Reps Resume Launch Of BI's Tradjenta; Judge Says FDA Regs Protect Byetta

09 Jun 2011

Roche/Ipsen's Suspended Taspoglutide Could Become Another Diabetes Casualty

10 Sep 2010

Amylin's Once-Weekly Bydureon Clears Major Cardiac Safety Hurdle

07 Jul 2011

Related Companies

Bristol Myers Squibb Company

Eli Lilly and Company

Boehringer Ingelheim GmbH

Sanofi

GSK plc

Novo Nordisk A/S

Merck & Co., Inc.

AstraZeneca PLC

Roche Holding AG

Takeda Pharmaceutical Co. Ltd.

Additional Topics

United States Legal Issues Deals BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.